 NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 PRNewswire -- Cyprium Therapeutics, Inc. Cyprium, a Fortress Biotech, Inc. Nasdaq: FBIO Fortress partner company, with support from its licensing partner Sentynl Therapeutics, Inc. Sentynl, a wholly owned subsidiary of Cadila Healthcare Limited Zydus, today announced positive results from an efficacy and safety analysis of data integrated from two completed pivotal studies in patients with Menkes disease treated with CUTX-101, copper histidinate CuHis. 